• Organizations: Eyebiotech Limited
Merck officially enters ophthalmic space with EyeBio acquisition
Business

Merck officially enters ophthalmic space with EyeBio acquisition

Pharmaceutical giant now owns Restoret (EYE103), an investigational, tri-specific antibody for DME and wet AMD.
Merck to acquire Eyebiotech in deal worth up to $3B
Business

Merck to acquire Eyebiotech in deal worth up to $3B

Agreement involves EyeBio’s lead retinal vascular disease candidate, Restoret, designed as an intravitreal injection for DME and wet AMD patients.
EyeBio presents positive data on Restoret from AMARONE trial for DME and wet AMD
Pipeline

EyeBio presents positive data on Restoret from AMARONE trial for DME and wet AMD

First-in-human study reports Wnt pathway agonist candidate to be well-tolerated, finding proof of concept established with visual and anatomical outcomes.
EyesBio expands financing for advanced development of Restoret
Pipeline

EyesBio expands financing for advanced development of Restoret

Funding now totals $130 million, supporting the ongoing phase 1b/2a AMARONE trial.
EyeBio doses first patients in phase 1b/2 trial for wet AMD, DME
Pipeline

EyeBio doses first patients in phase 1b/2 trial for wet AMD, DME

AMARONE trial is evaluating the potential of Restoret to leakage associated with the unmet needs of this patient base.
Global collaboration to develop immunoglobulin eye drops for DED
Research

Global collaboration to develop immunoglobulin eye drops for DED

UIC’s Selagine, Inc. and Grifols will manage a clinical development program based on FDA approval.
Eyebiotech Limited introduces first retinal disease candidate
Pipeline

Eyebiotech Limited introduces first retinal disease candidate

Restoret, the company’s lead asset, is designed to target retinal diseases characterized by vascular leakage via intravitreal injection.